Microsaic Systems plc Exclusive US and Canada Distribution Agreement (5382G)

TIDMMSYS

RNS Number : 5382G

Microsaic Systems plc

07 November 2018

7 November 2018

Microsaic Systems plc

("Microsaic" or the "Company")

Exclusive US and Canada Distribution Agreement with Spark Holland Inc doing business as iChrom Solutions

Microsaic Systems plc (AIM: MSYS), the developer of point of need mass spectrometry ("MS") instruments, is pleased to announce that it has signed an exclusive distribution agreement with Spark Holland Inc doing business as iChrom Solutions ("iChrom") to distribute Microsaic-branded 4500 MiD(R) MS detector in the US and Canada.

As a full-service instrument distributor, iChrom serves several industries including drugs of abuse (DOA), clinical chemistry, and drug development in both the small molecule pharmaceutical area and protein characterization. iChrom's targeted industries include environmental toxicology and forensic/DOA toxicology testing.

iChrom has developed strategic partner relationships with several global instrument and consumable suppliers to expand offerings for a more comprehensive portfolio of high-quality instruments and accessories. These notable partners include Knauer Wissenschaftliche Geraete GmbH, Spark Holland BV, Axel Semrau GmbH & Co. KG, DataApex and American Chromatography. The combination of iChrom's instrument portfolio focus and its expertly trained staff delivers a dedicated and bespoke service with a successful track record.

Glenn Tracey, CEO of Microsaic, commented, "I am extremely pleased to partner with iChrom to distribute our compact, point of need MS technology, alongside their impressive technology portfolio. The team at iChrom has the in-depth technical expertise, and full reach of end user applications, particularly in drugs of abuse and small molecule pharmaceuticals.

"Clearly, North America is a well-established market for analytical chemistry, and this marks another milestone in what we expect to be a very exciting period of growth for Microsaic, now with seven distribution and OEM agreements signed in 2018 across North America, Europe, China, Taiwan and Malaysia"

John Crutchfield, President of iChrom, added: "The added sensitivity and selectivity provided by the unique design of the 4500 MiD MS detector offers our diverse clientele more flexibility in the types of samples they can analyze. Combined with our other hyphenated chromatography techniques of UHPLC, online SPE, and advanced sample processing, we now provide our clients with a fully automated analytical system capable of handling some of the most challenging sample matrices in the marketplace."

 
 Enquiries: 
 Microsaic Systems plc 
  Glenn Tracey, CEO 
  Bevan Metcalf, FD                    [phone] 
  N+1 Singer (Nominated Adviser & 
   Broker) 
   Shaun Dobson (Corporate Finance) 
   Tom Salvesen (Corporate Broking)     [phone] 
 IFC Advisory Ltd (Financial PR) 
  Graham Herring 
  Heather Armstrong 
  Florence Chandler                     [phone] 
 

About Microsaic Systems

Microsaic Systems plc (AIM: MSYS) is a high technology company developing chip-based, bench-top and point-of-analysis mass spectrometry ("MS") instruments that are designed to improve the efficiency of pharmaceutical R&D and manufacturing. The Company is working with established global life science companies to co-develop new solutions to improve productivity in the development of small molecule and novel biologic (peptides, antibodies) medicines. MS is a powerful method of analysis to enable earlier decision making relating to product identification, purity and bioactivity, and is the analytical technique of choice for biochemists across many industry sectors.

Microsaic's core product, the 4500 MiD(R), is a robust and compact MS system, retaining the functionality of larger conventional MS systems, is easier to use by non-specialists, consumes less energy and has lower running costs. For more information, please go to www.microsaic.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

AGRQQLFBVFFXFBE

(END) Dow Jones Newswires

November 07, 2018 02:00 ET (07:00 GMT)